PTC Therapeutics Showcases Sephience as Potential New Standard of Care for PKU in Corporate Presentation

Reuters

2025/11/05

PTC <a href="https://laohu8.com/S/LENZ">Therapeutics</a> Showcases Sephience as Potential <a href="https://laohu8.com/S/NSE.AU">New Standard</a> of Care for PKU in Corporate Presentation

PTC Therapeutics Inc. provided an update highlighting the commercial launch and early performance of Sephience, its therapy for phenylketonuria (PKU). The company reported $19.6 million in global revenue from Sephience, with $14.4 million generated in the US and $5.2 million from ex-US markets. As of September 30, 2025, 341 patients were on commercial therapy worldwide, with 521 Patient Start Forms submitted by 141 unique US prescribers. Sephience demonstrated clinically significant reductions in blood phenylalanine (Phe) levels, showing superior Phe lowering compared to sapropterin (BH4) in head-to-head studies. Additional marketing authorization reviews for Sephience are ongoing, including a decision expected in Japan in the fourth quarter of 2025. The company also noted a strong balance sheet and the ability to support future commercial launches and research initiatives without additional capital. You can access the full presentation through the link below.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. PTC Therapeutics Inc. published the original content used to generate this news brief on November 05, 2025, and is solely responsible for the information contained therein.

應版權方要求，你需要登入查看該內容

登入 / 註冊

免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。

熱議股票

1
2
3
4
5
6
7
8
9
10

{"basename":"/hant","ssrTDKData":{"titleTemplate":"%s - 老虎證券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎證券,老虎證券開戶,老虎券商,老虎證券官網,老虎證券app,tigertrade老虎證券,股票,炒股,新加坡股票交易平臺,投資,投資理財","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hant/news/2581713588"},"companyName":"老虎證券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2581713588\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2581713588?lang=zh_TW&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-11-05 10:47","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2581713588","market":"fut","top_or_hot":-1,"title":"PTC Therapeutics Showcases Sephience as Potential New Standard of Care for PKU in Corporate Presentation","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      PTC <a href=\"https://laohu8.com/S/LENZ\">Therapeutics</a> Showcases Sephience as Potential <a href=\"https://laohu8.com/S/NSE.AU\">New Standard</a> of Care for PKU in Corporate Presentation\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        <a href=\"https://laohu8.com/S/PTCT\">PTC Therapeutics Inc.</a> provided an update highlighting the commercial launch and early performance of Sephience, its therapy for phenylketonuria (PKU). The company reported $19.6 million in global revenue from Sephience, with $14.4 million generated in the US and $5.2 million from ex-US markets. As of September 30, 2025, 341 patients were on commercial therapy worldwide, with 521 Patient Start Forms submitted by 141 unique US prescribers. Sephience demonstrated clinically significant reductions in blood phenylalanine (Phe) levels, showing superior Phe lowering compared to sapropterin (BH4) in head-to-head studies. Additional marketing authorization reviews for Sephience are ongoing, including a decision expected in Japan in the fourth quarter of 2025. The company also noted a strong balance sheet and the ability to support future commercial launches and research initiatives without additional capital. You can access the full presentation through the link below.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. PTC Therapeutics Inc. published the original content used to generate this news brief on November 05, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>PTC Therapeutics Showcases Sephience as Potential New Standard of Care for PKU in Corporate Presentation</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nPTC Therapeutics Showcases Sephience as Potential New Standard of Care for PKU in Corporate Presentation\n</h2>\n<h4 class=\"meta\">\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time smaller\">2025-11-05 10:47</p>\n</div>\n</a>\n</h4>\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      PTC <a href=\"https://laohu8.com/S/LENZ\">Therapeutics</a> Showcases Sephience as Potential <a href=\"https://laohu8.com/S/NSE.AU\">New Standard</a> of Care for PKU in Corporate Presentation\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        <a href=\"https://laohu8.com/S/PTCT\">PTC Therapeutics Inc.</a> provided an update highlighting the commercial launch and early performance of Sephience, its therapy for phenylketonuria (PKU). The company reported $19.6 million in global revenue from Sephience, with $14.4 million generated in the US and $5.2 million from ex-US markets. As of September 30, 2025, 341 patients were on commercial therapy worldwide, with 521 Patient Start Forms submitted by 141 unique US prescribers. Sephience demonstrated clinically significant reductions in blood phenylalanine (Phe) levels, showing superior Phe lowering compared to sapropterin (BH4) in head-to-head studies. Additional marketing authorization reviews for Sephience are ongoing, including a decision expected in Japan in the fourth quarter of 2025. The company also noted a strong balance sheet and the ability to support future commercial launches and research initiatives without additional capital. You can access the full presentation through the link below.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. PTC Therapeutics Inc. published the original content used to generate this news brief on November 05, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"LU0109394709.USD","symbol_name":"富蘭克林生物科技新領域基金A (acc)","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251105:nNDL4xSMdn:1","article_id":"2581713588","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2581713588","pubTimestamp":1762310859,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"PTC Therapeutics Inc. provided an update highlighting the commercial launch and early performance of Sephience, its therapy for phenylketonuria . The company reported $19.6 million in global revenue from Sephience, with $14.4 million generated in the US and $5.2 million from ex-US markets. As of September 30, 2025, 341 patients were on commercial therapy worldwide, with 521 Patient Start Forms submitted by 141 unique US prescribers. Sephience demonstrated clinically significant reductions in blood phenylalanine  levels, showing superior Phe lowering compared to sapropterin  in head-to-head studies. Additional marketing authorization reviews for Sephience are ongoing, including a decision expected in Japan in the fourth quarter of 2025. The company also noted a strong balance sheet and the ability to support future commercial launches and research initiatives without additional capital. You can access the full presentation through the link below.","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"LU0109394709.USD":"富兰克林生物科技新领域基金A (acc)","BK4139":"生物科技","LU0889565916.HKD":"FRANKLIN BIOTECHNOLOGY DISCOVERY \"A\" (HKD) ACC","LU0320765992.SGD":"FTIF - Franklin Biotechnology Discovery A Acc SGD","PTCT":"PTC Therapeutics Inc."},"translate_title":"PTC Therapeutics在企业演示中展示Sephience作为PKU潜在的新护理标准","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"PTCT":0.9},"content_text":"PTC Therapeutics Showcases Sephience as Potential New Standard of Care for PKU in Corporate Presentation\n    \n\nPTC Therapeutics Inc. provided an update highlighting the commercial launch and early performance of Sephience, its therapy for phenylketonuria (PKU). The company reported $19.6 million in global revenue from Sephience, with $14.4 million generated in the US and $5.2 million from ex-US markets. As of September 30, 2025, 341 patients were on commercial therapy worldwide, with 521 Patient Start Forms submitted by 141 unique US prescribers. Sephience demonstrated clinically significant reductions in blood phenylalanine (Phe) levels, showing superior Phe lowering compared to sapropterin (BH4) in head-to-head studies. Additional marketing authorization reviews for Sephience are ongoing, including a decision expected in Japan in the fourth quarter of 2025. The company also noted a strong balance sheet and the ability to support future commercial launches and research initiatives without additional capital. You can access the full presentation through the link below.\n      \n\nDisclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. PTC Therapeutics Inc. published the original content used to generate this news brief on November 05, 2025, and is solely responsible for the information contained therein.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"productRelease","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":true,"code":"91000000","status":"200"}}}